Incretin-based therapies for type 2 diabetes mellitus in Asian patients: Analysis of clinical trials

Medical Journal of Indonesia

Volumn 19, Issue 3, 2010, Pages 205-212

  Louisa, Melva ^a   Takeuchi, Madoka ^b   Takeuchi, Masahiro ^b   Nafrialdi, ^a   Setiabudy, Rianto ^a  

^a UNIVERSITY OF INDONESIA   (Indonesia)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Exenatide; Incretin; Liraglutide; Sitagliptin; Type 2 diabetes; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INCRETIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; VILDAGLIPTIN;

ARTICLE; ASIAN; CAUCASIAN; CHINESE; DRUG EFFICACY; DRUG SAFETY; GLUCOTOXICITY; GLYCEMIC CONTROL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INDIAN; INSULIN RESISTANCE; JAPANESE (PEOPLE); KOREAN (PEOPLE); LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 85008656000     PISSN: 08531773     EISSN: 22528083     Source Type: Journal    
DOI: 10.13181/mji.v19i3.406     Document Type: Article

References (40)

1. Ramachandran A, Ma RCW, Snehalatha C. Diabetes in Asia. Article in Press. Lancet. October 28, 2009.
2. Wild S, Roglic G, Green A, Sicree R, King G. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diab Care. 2004; 27:1047-52.
3. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006; 368:1681-8.
4. Cockram CS. Diabetes mellitus: perspective from the Asia-Pacific region. Diab Res Clin Pract. 2000;50 (Suppl 2): S3-7.
5. Unger RH, Zhou YT. Lipotoxicity of beta cells in obesity and in other cause of fatty acid spillover. Diabetes. 2001; 1: S118-21.
6. Chturvedi N, Stevens LK, Fuller JH, Lee ET, Lu M. The WHO Multinational Study Group, Risk factors, ethnic differences and mortality associated with lowerextremity gangrene and amputation in diabetes. The WHO multinational study of vascular disease in diabetes. Diabetologia. 2001; 44 (Suppl 2): S65-71.
7. Lee ET, Keen H, Bennett PH, Fuller JH, Lu M. The WHO Multinational Study Group, WHO Multinational Study Group: Follow-up of the WHO Multinational study of vascular disease in diabetes: general description and morbidity. Diabetologia. 2001; 44 (Suppl 2): S3:13.
8. The DECODE-DECODA Study Group, Age, body mass index and type 2 diabetes: associations modified by ethnicity, Diabetologia. 2003; 46: 1063-70.
9. The DECODA study Group. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diab Care. 2003; 26: 1770-80.
10. Seino Y. Relevance of incretins in the treatment of Asian patients with Type 2 diabetes. Diab Res Clin Pract. 2008; 79: S4.
11. Takeuchi M, Okamoto K, Takagi T, Ishii H. Ethnic difference in patients with type 2 diabetes mellitus in inter-East Asian populations: A systematic review and metaanalysis focusing on fasting serum insulin. Diab Res Clin Pract. 2008; 81: 370-6.
12. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diab Res Clin Pract. 2004; 66S: S37-43.
13. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009; 297: 127-36.
14. Nauck M, Stockman F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986; 29: 46-52.
15. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: Therapeutic potential, patient selection and clinical use. Am J Med. 2009; 122: S37-50.
16. Verspohl EJ. Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagons-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharm Ther. 2009; 124: 113-38.
17. Gao Y, Yoon KH, Chiang LM, Mohan V, Ning G, Shah S, et al. Efficacy and safety of exenatide in patients of Asian descent with type2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diab Res Clin Pract. 2009; 83: 69-76.
18. Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, et al. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J. 2009; 56:415-24.
19. Iwamoto K, Nasu R, Yamamura A, Kothare PA, Mace K, Wolka AM, Linnebjerg H. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J. August 25, 2009.
20. Khoo J, Rayner CK, Jones KL, Horowitz M. Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag. 2009;5: 683-98.
21. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dosedependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A doubleblind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diab Res Clin Pract. 2008;81:161-8.
22. Seino Y, Rasmussen MF, Katayama Y, Kaku K. Liraglutide is statistically superior to glibenclamide at controlling glycemia and weight, with low hypoglycemic risk, and improves beta-cell function in Japanese subjects with T2D; Abstracts of the American Diabetes Association (ADA) 69th scientific session. 2009. Abstract 536-P.
23. Seino Y, Rasmussen MF, Katayama Y, Kaku K. The human GLP-1 analogue liraglutide given once daily provides excellent metabolic control in Japanese patients either as monotherapy or in combination with SU during 52 weeks of treatment. Diabetologia. 2009; 52 (Suppl 1): S292.
24. Iwamoto Y, Nonaka K, Okada A, Okuyama K, Stein PP. Dose-response relationship for glycemic efficacy, safety and tolerability of sitagliptin after 12 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Diabetologia. 2007; 50 (Suppl 1): S366.
25. Kadowaki T, Tajima N, Odawara M, Nishii M, Nonaka K, Stein PP. Sitagliptin added to ongoing treatment with metformin improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes (T2DM); Abstracts of the American Diabetes Association (ADA) 68th scientific session. 2008. Abstract 2135-PO.
26. Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India and Korea. Diab Res Clin Pract. 2009; 83:106-16.
27. Chan JCN, Scott R, Ferreira JCA, Sheng D, Gonzales E, Davies MJ, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diab Obes Metab. 2008; 10: 545-55.
28. Maegawa H, Kashiwagi A, Tajima N, Kadowaki T, Nonaka K, Okamoto T. Diabetologia. 2008; 51 (Suppl 1): 365.
29. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, et al. Diab Res Clin Pract. 2008; 79: 291-8.
30. NCT00411554. Study of Sitagliptin in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy. Available URL: www.clinicaltrials.gov
31. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diab Res Clin Pract. 2009; 83: 233-40.
32. DeFronzo D, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diab Care. 2005; 28: 1092-100.
33. Kendall DM, Riddle MC, Rosenstock J, Zuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diab Care. 2005; 28: 1083-91.
34. Marre M, Shaw J, Brandle M, Bebakar WMW, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26: 268-78.
35. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effct of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diab Care. 2006; 29: 2632-7.
36. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49: 2564-71.
37. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diab Care. 2006; 29: 2638-43.
38. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diab Res Clin Pract. 2007; 76: 132-8.
39. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA2c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med. 2007; 24: 955-61.
40. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycemic control and bodyweight in subjects with type 2 diabetes. Diabet Med. 2005; 22: 1016-23.